Moontpellier Cancer Research Institute
Campus Val d’Aurelle,
During the 2007-2017 period, Montpellier has witnessed a rapid growth of its cancer research community, in particular at the ICM Cancer Hospital Campus. Created in 2008 and localized on the ICM Campus, the Montpellier Cancer Research Institute (U1194) is at the core of this expansion and a key player in cross-cutting initiatives, such as SIRIC, that have boosted cancer research in Montpellier. IRCM offers a stimulating and interactive environment to perform cancer research in close connection with the ICM. It is still a young structure with an emergent project and a still ongoing high rate of new team recruitment. Hence, IRCM’s commitment is to undertake the highest quality fundamental and translational research to ultimately improve outcomes for cancer patients. IRCM is jointly operated by INSERM, the University of Montpellier and ICM. It functions as an integrated research facility with staff from INSERM, CNRS, Universities, ICM and CHU sharing technical facilities and platforms, support services and expertise. Within its 4,000 m2 building fully connected to the Cancer Hospital, IRCM currently hosts hosts approximately 205 people divided into 17 research teams, technological platform and research support service.
Most IRCM standard technical facilities (Proteomics, Animal Imaging (micro-PET-CT, SPEC-CT, Lum, cytometry, animal house dedicated to cancer models, cellular screening, microscopy and histology) are part of Montpellier Biocampus network. Within the frame of SIRIC1, IRCM has also developed 3 new top notch innovative platforms for cancer research, unique in Montpellier: i/ to develop preclinical tumorgrafts models (PDTX and orthotopic xenografts), ii/ to generate genetically engineered monoclonal antibodies (GenAc, also supported by Inserm transfert), and iii/ to perform controlled irradiation of cells and preclinical models. In addition, IRCM building currently hosts the department of Medical Biometry of ICM, the Translational Research Unit (URT) of ICM, the Herault cancer registry, and three biotech startups dedicated to cancer and created by scientists from IRCM and ICM (DiaDX, Imab, OREGA, NovaGray)